tiprankstipranks
Medpace Holdings (MX:MEDP)
:MEDP
Mexico Market

Medpace Holdings (MEDP) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

MEDP Analyst Ratings

Hold
11Ratings
Hold
2 Buy
9 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Medpace
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MEDP Stock 12 Month Forecast

Average Price Target

$10,120.53
▲(13.03% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Medpace Holdings in the last 3 months. The average price target is $10,120.53 with a high forecast of $12,070.68 and a low forecast of $7,849.43. The average price target represents a 13.03% change from the last price of $8,954.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5879":"$5,879","7427":"$7,427","8975":"$8,975","10523":"$10,523","12071":"$12,071"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12070.67975728,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10120.532362967999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7849.430478,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5879,7427,8975,10523,12071],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7022.03,7410.387673636923,7798.745347273846,8187.103020910769,8575.460694547692,8963.818368184615,9352.176041821538,9740.533715458461,10128.891389095385,10517.249062732308,10905.606736369231,11293.964410006154,11682.322083643077,{"y":12070.67975728,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7022.03,7260.376335612923,7498.722671225846,7737.0690068387685,7975.415342451692,8213.761678064615,8452.108013677538,8690.454349290461,8928.800684903385,9167.147020516306,9405.493356129231,9643.839691742152,9882.186027355076,{"y":10120.532362967999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7022.03,7085.676190615384,7149.322381230769,7212.968571846153,7276.614762461539,7340.260953076923,7403.907143692308,7467.553334307692,7531.199524923077,7594.845715538461,7658.491906153846,7722.138096769231,7785.784287384616,{"y":7849.430478,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5880,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5880,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5880,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5880,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5880,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7022.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7022.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7022.03,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12,071Average Price Target$10,121Lowest Price Target$7,849
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on MX:MEDP
Mizuho Securities
Mizuho Securities
$11,599.71
Buy
29.55%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), NeuroPace (NASDAQ: NPCE) and Cardinal Health (NYSE: CAH)
Truist Financial Analyst forecast on MX:MEDP
Truist Financial
Truist Financial
$10,622.9
Hold
18.64%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH) and Medpace Holdings (NASDAQ: MEDP)
BMO Capital Analyst forecast on MX:MEDP
BMO Capital
BMO Capital
$10,465.91
Hold
16.89%
Upside
Reiterated
07/27/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Robert W. Baird Analyst forecast on MX:MEDP
Robert W. Baird
Robert W. Baird
$9,541.42$10,884.54
Hold
21.56%
Upside
Reiterated
07/24/26
Medpace price target raised to $624 from $547 at BairdMedpace price target raised to $624 from $547 at Baird
TD Cowen
$7,308.69$8,582.04
Hold
-4.15%
Downside
Assigned
07/23/26
Charles Rhyee Maintains Hold Rating, Raises Price Target to $492 Amid Near-Term Strength and 2027 Metabolic Concentration Risks
William Blair Analyst forecast on MX:MEDP
William Blair
William Blair
Hold
Reiterated
07/23/26
Medpace Rally and Record Bookings Prompt Valuation Caution as Haase Reiterates Hold Rating
Leerink Partners Analyst forecast on MX:MEDP
Leerink Partners
Leerink Partners
$8,983.24$10,814.77
Hold
20.78%
Upside
Reiterated
07/23/26
Medpace price target raised to $620 from $515 at LeerinkMedpace price target raised to $620 from $515 at Leerink
Barclays Analyst forecast on MX:MEDP
Barclays
Barclays
$7,849.43
Hold
-12.34%
Downside
Reiterated
07/23/26
Barclays Reaffirms Their Hold Rating on Medpace Holdings (MEDP)
RBC Capital Analyst forecast on MX:MEDP
RBC Capital
RBC Capital
$8,442.5$12,070.68
Buy
34.81%
Upside
Reiterated
07/23/26
RBC Capital Sticks to Their Buy Rating for Medpace Holdings (MEDP)
Deutsche Bank  Analyst forecast on MX:MEDP
Deutsche Bank
Deutsche Bank
$8,372.73$9,332.1
Hold
4.22%
Upside
Reiterated
07/23/26
Medpace price target raised to $535 from $480 at Deutsche BankMedpace price target raised to $535 from $480 at Deutsche Bank
Jefferies Analyst forecast on MX:MEDP
Jefferies
Jefferies
$8,547.16$8,983.24
Hold
0.33%
Upside
Downgraded
07/07/26
Medpace downgraded to Hold from Buy at JefferiesMedpace downgraded to Hold from Buy at Jefferies
Rothschild & Co Redburn Analyst forecast on MX:MEDP
Rothschild & Co Redburn
Rothschild & Co Redburn
$5,965.57$8,268.07
Hold
-7.66%
Downside
Downgraded
09/03/25
Redburn Atlantic downgrades Medpace Holdings (MEDP) to a Hold
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on MX:MEDP
Mizuho Securities
Mizuho Securities
$11,599.71
Buy
29.55%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), NeuroPace (NASDAQ: NPCE) and Cardinal Health (NYSE: CAH)
Truist Financial Analyst forecast on MX:MEDP
Truist Financial
Truist Financial
$10,622.9
Hold
18.64%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH) and Medpace Holdings (NASDAQ: MEDP)
BMO Capital Analyst forecast on MX:MEDP
BMO Capital
BMO Capital
$10,465.91
Hold
16.89%
Upside
Reiterated
07/27/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Robert W. Baird Analyst forecast on MX:MEDP
Robert W. Baird
Robert W. Baird
$9,541.42$10,884.54
Hold
21.56%
Upside
Reiterated
07/24/26
Medpace price target raised to $624 from $547 at BairdMedpace price target raised to $624 from $547 at Baird
TD Cowen
$7,308.69$8,582.04
Hold
-4.15%
Downside
Assigned
07/23/26
Charles Rhyee Maintains Hold Rating, Raises Price Target to $492 Amid Near-Term Strength and 2027 Metabolic Concentration Risks
William Blair Analyst forecast on MX:MEDP
William Blair
William Blair
Hold
Reiterated
07/23/26
Medpace Rally and Record Bookings Prompt Valuation Caution as Haase Reiterates Hold Rating
Leerink Partners Analyst forecast on MX:MEDP
Leerink Partners
Leerink Partners
$8,983.24$10,814.77
Hold
20.78%
Upside
Reiterated
07/23/26
Medpace price target raised to $620 from $515 at LeerinkMedpace price target raised to $620 from $515 at Leerink
Barclays Analyst forecast on MX:MEDP
Barclays
Barclays
$7,849.43
Hold
-12.34%
Downside
Reiterated
07/23/26
Barclays Reaffirms Their Hold Rating on Medpace Holdings (MEDP)
RBC Capital Analyst forecast on MX:MEDP
RBC Capital
RBC Capital
$8,442.5$12,070.68
Buy
34.81%
Upside
Reiterated
07/23/26
RBC Capital Sticks to Their Buy Rating for Medpace Holdings (MEDP)
Deutsche Bank  Analyst forecast on MX:MEDP
Deutsche Bank
Deutsche Bank
$8,372.73$9,332.1
Hold
4.22%
Upside
Reiterated
07/23/26
Medpace price target raised to $535 from $480 at Deutsche BankMedpace price target raised to $535 from $480 at Deutsche Bank
Jefferies Analyst forecast on MX:MEDP
Jefferies
Jefferies
$8,547.16$8,983.24
Hold
0.33%
Upside
Downgraded
07/07/26
Medpace downgraded to Hold from Buy at JefferiesMedpace downgraded to Hold from Buy at Jefferies
Rothschild & Co Redburn Analyst forecast on MX:MEDP
Rothschild & Co Redburn
Rothschild & Co Redburn
$5,965.57$8,268.07
Hold
-7.66%
Downside
Downgraded
09/03/25
Redburn Atlantic downgrades Medpace Holdings (MEDP) to a Hold
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medpace Holdings

3 Months
Ann HynesMizuho Securities
Success Rate
5/11 ratings generated profit
45%
Average Return
+6.03%
Copying Ann Hynes's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +6.03% per trade.
1 Year
Ann HynesMizuho Securities
Success Rate
9/11 ratings generated profit
82%
Average Return
+24.62%
Copying Ann Hynes's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +24.62% per trade.
2 Years
Ann HynesMizuho Securities
Success Rate
10/11 ratings generated profit
91%
Average Return
+35.89%
Copying Ann Hynes's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +35.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MEDP Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
6
9
6
5
6
Hold
6
11
7
6
12
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
13
21
13
11
18
In the current month, MEDP has received 6 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. MEDP average Analyst price target in the past 3 months is 10,120.53.
Each month's total comprises the sum of three months' worth of ratings.

MEDP Financial Forecast

MEDP Earnings Forecast

Next quarter’s earnings estimate for MEDP is $77.07 with a range of $75.30 to $81.01. The previous quarter’s EPS was $74.20. MEDP beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 54.55% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.
Next quarter’s earnings estimate for MEDP is $77.07 with a range of $75.30 to $81.01. The previous quarter’s EPS was $74.20. MEDP beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 54.55% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.

MEDP Sales Forecast

Next quarter’s sales forecast for MEDP is $12.47B with a range of $12.33B to $12.85B. The previous quarter’s sales results were $12.35B. MEDP beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 63.64% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.
Next quarter’s sales forecast for MEDP is $12.47B with a range of $12.33B to $12.85B. The previous quarter’s sales results were $12.35B. MEDP beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 63.64% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.

MEDP Stock Forecast FAQ

What is MX:MEDP’s average 12-month price target, according to analysts?
Based on analyst ratings, Medpace Holdings’s 12-month average price target is 10,120.53.
    What is MX:MEDP’s upside potential, based on the analysts’ average price target?
    Medpace Holdings has 13.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Medpace Holdings a Buy, Sell or Hold?
          Medpace Holdings has a consensus rating of Hold, which is based on 2 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Medpace Holdings’s share price target?
            The average share price target for Medpace Holdings is 10,120.53. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $12,070.68 ,and the lowest forecast is $7,849.43. The average share price target represents 13.03% Increase from the current price of $8,954.01.
              What do analysts say about Medpace Holdings?
              Medpace Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Medpace Holdings?
                To buy shares of MX:MEDP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.